Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
- Details
- Category: Sanofi
Sanofi and GSK today started the Phase 1/2 clinical trial for their adjuvanted COVID-19 vaccine. The vaccine candidate, developed in partnership by Sanofi and GSK, uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza vaccines with GSK's established pandemic adjuvant technology.
New collaboration between Novartis and Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicines
- Details
- Category: Novartis
Novartis and the African Union (AU) through the Africa Medical Supplies Platform (AMSP) have announced a new collaboration to facilitate the supply of medicines from the Novartis Pandemic Response Portfolio to the AU member states and Caricom countries.
Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups
- Details
- Category: AstraZeneca
AZD1222 development expanded into a Phase III clinical trial in the US to assess its safety, efficacy and immunogenicity.1)
The US trial, called D8110C00001, is funded by the Biomedical Advanced Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) and the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health, and led by AstraZeneca.
Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.
- Details
- Category: Sanofi
Sanofi today announced that the global Phase 3 trial investigating intravenously administered Kevzara® (sarilumab) at a dose of 200 mg or 400 mg[1] in severely or critically ill[2] patients hospitalized with COVID-19 did not meet its primary endpoint and key secondary endpoint[3] when Kevzara was compared to placebo added to usual hospital care.
Vir Biotechnology and GSK start phase 2/3 study of COVID-19 antibody treatment
- Details
- Category: GlaxoSmithKline
Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced that the first patient was dosed last week in a phase 2/3 study with VIR-7831 (also known as GSK4182136), a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody, for the early treatment of COVID-19 in patients who are at high risk of hospitalisation.
Abbott's fast, $5, 15-minute, easy-to-use COVID-19 antigen test receives FDA Emergency Use Authorization
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its BinaxNOW™ COVID-19 Ag Card rapid test for detection of COVID-19 infection. Abbott will sell this test for $5. It is highly portable (about the size of a credit card), affordable and provides results in 15 minutes.
Europe's largest initiative launches to accelerate therapy development for COVID-19 and future coronavirus threats
- Details
- Category: Boehringer Ingelheim
CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19. With a grant totaling € 77.7 million, CARE is funded by
More Pharma News ...
- Phase I clinical trial initiated for monoclonal antibody combination for the prevention and treatment of COVID-19
- Bayer and Informed Data Systems Inc. (One Drop) join forces to jointly develop digital health products across therapeutic areas
- Pfizer and BioNTech share positive early data on lead mRNA vaccine candidate BNT162b2 against COVID-19
- Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19
- Sanofi to acquire Principia Biopharma
- AstraZeneca concludes agreement with the European Commission for the supply of up to 400 million doses of AZD1222 COVID-19 vaccine
- Johnson & Johnson announces agreement with U.S. government for 100 million doses of investigational COVID-19 vaccine